Furo

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Furo

What is Furo? (Mometasone Furoate)

Property Description
Active ingredient Mometasone Furoate
Form Aqueous Nasal Spray (Metered-Dose Suspension)
Pharmacological Class Glucocorticoid (Corticosteroid)
General Purpose Managing nasal inflammation and irritation
Origin Synthetic
Status Prescription-only medicine (Rx)

What Type of Medicine is Furo and What is it Made Of?

Furo is a prescription-only, single-ingredient pharmaceutical product containing the potent synthetic corticosteroid, Mometasone Furoate, delivered as a metered-dose aqueous nasal spray. The product’s core identity is defined by its active substance, Mometasone Furoate, which is classified within the Glucocorticoid pharmacological class, a subset of corticosteroids recognized for their strong anti-inflammatory properties. The medicine is typically positioned as a prescription-only medicine (Rx) for individuals requiring a high-potency topical steroid formulation. The formulation is specifically an aqueous suspension, ensuring the active particles are localized on the nasal mucosal surface following intranasal administration. The formulation exhibits high topical potency and rapid clearance upon systemic absorption, a design feature minimizing unwanted widespread effects. This indicates that the medicine is highly specialized to act locally and intensely where it is applied.


Understanding the General Purpose of Furo

The general purpose of Furo is to manage and relieve symptoms associated with persistent inflammation and irritation in the nasal passages through its powerful localized action. As a potent glucocorticoid, its primary function is to suppress the local inflammatory processes that cause the nasal lining to swell and become irritated, thereby restoring a more comfortable physiological state. This localized anti-inflammatory action is intended for addressing the underlying cause of persistent nasal issues, rather than just masking symptoms. For example, it is used for providing relief in scenarios where patients experience chronic nasal swelling and congestion. This confirms the medicine's role is to resolve the biological reaction, resulting in the abatement of congestion and fluid production.

Regulatory References

  1. NIH DailyMed Label for Mometasone Furoate

What side effects are possible with Furo?

Possible Side Effects and Safety Information

The safety profile for Furo (Mometasone Furoate Nasal Spray) is officially classified by regulatory bodies, distinguishing between commonly experienced local reactions and potential systemic effects typical of the glucocorticoid class. The most frequent adverse reactions noted in clinical trials include headache, pharyngitis (sore throat), epistaxis (nosebleeds), viral infection, and cough.

Documented Safety Considerations

The official labeling documents potential adverse reactions by the physiological systems involved, such as the respiratory, nervous system, immune system, and endocrine system disorders.

Classification Documented Safety Points
Serious Reactions Risks documented in regulatory sources include nasal septum perforation, adrenal suppression (HPA axis effects), glaucoma and cataracts (associated with long-term use), and severe hypersensitivity reactions (including wheezing).
Localized Risks Potential for nasal irritation or ulceration, as well as localized infection with Candida albicans (a fungal infection) within the nose or throat

Duration and Population Constraints

Safety notes explicitly state that certain effects, such as ocular disorders (glaucoma/cataracts), are associated with long-term use of nasal corticosteroids. The medicine is generally contraindicated in patients with an untreated localized infection involving the nasal mucosa. For pediatric patients, regulatory documents specify the potential for a reduction in growth velocity. Official documentation mandates periodic examination of the nasal mucosa for patients using the spray for several months or longer.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for Mometasone Furoate Nasal Spray indicates that the potential for a severe acute overdose resulting from a single excessive dose is low due to minimal systemic absorption following intranasal administration.


Documented Overdose Concerns

The primary documented concern arises from the prolonged use of doses higher than officially recommended. This chronic overuse may lead to systemic effects of corticosteroids, specifically affecting the endocrine system. The official labeling states that this can result in Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Hypercorticism, which is consistent with Cushing's syndrome.

Overdose Context Regulatory Statement
Pediatric Risk Children using excessive doses for extended periods require monitoring for potential growth retardation
Antidote No specific antidote is known

Required Emergency Actions

Immediate medical attention must be sought for any suspected overdose or if signs of a severe hypersensitivity reaction occur, such as sudden swelling of the face, throat, or difficulty breathing. The official guidance requires that individuals contact a Poison Control Center right away for suspected misuse or overdose. Management is generally described as symptomatic and supportive treatment. If chronic overuse has resulted in HPA-axis suppression, the treatment approach involves the slow, gradual discontinuation of the nasal spray, along with periodic patient monitoring.

Therapeutic Uses of Furo

What Furo Treats: Main Uses and Benefits

This medicine is commonly used in situations involving certain distressing symptoms, generally contributing to eased discomfort during periods of heightened symptoms. Furo is considered relevant for easing two primary therapeutic domains: allergic rhinitis and nasal polyposis.

Treating Moderate-to-Severe Allergic Symptoms

The medicine helps address symptom clusters that may become intense or disruptive in conditions presenting with acute episodes of Seasonal Allergic Rhinitis (hay fever) and Perennial Allergic Rhinitis (year-long allergies). Specifically, it is used to manage nasal symptoms like a stuffy or runny nose, frequent sneezing, and nasal itching. The medicine is commonly used for prophylactic purposes to help maintain a sense of stability when symptoms are more noticeable.

Managing Obstruction and Providing Sustained Support

Furo is also applied in settings marked by temporary physiological imbalance to support the management of nasal polyps in adults. In situations where symptoms are related to inflammatory or irritative states within the nose, the medication may assist with maintaining functional stability and contributes to easing the overall symptom load during symptomatic periods, particularly regarding airflow. This supportive relief helps improve day-to-day comfort.

Quick Fact: Relief for Congestion
This medicine is commonly used in contexts where nasal congestion and obstruction are the main physical discomforts, especially in moderate-to-severe symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility Rules for Furo (Mometasone Furoate)

The patient population for Furo is strictly defined by regulatory documents, which detail who is allowed to use the medicine, who is restricted, and who is absolutely prohibited from use.

Contraindicated Populations:

  • Patients with known hypersensitivity (allergy) to mometasone furoate or any of the product's inactive ingredients are strictly prohibited from use.

Age-Related Eligibility:

  • Use for Allergic Rhinitis is approved for patients 2 years of age and older (FDA) or 3 years of age and older (SmPC). Safety and effectiveness are not established below these ages.
  • Treatment for Nasal Polyps is reserved for adults, meaning patients 18 years of age and older.
  • Growth must be monitored in pediatric patients, as use may be associated with a reduction in growth velocity.

Condition-Specific Restrictions:

  • The medicine should be avoided until healing is complete in patients who have experienced recent nasal surgery, nasal trauma, or nasal septum ulcers.
  • Use is restricted and requires caution, or is advised against, in patients with active or quiescent tuberculosis or untreated systemic infections (e.g., fungal, bacterial, viral, or ocular herpes simplex).
  • For Pregnancy and Lactation, use is not recommended unless the potential benefit to the mother justifies the risk to the fetus or infant; a decision to discontinue either breastfeeding or therapy is required.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents outline specific interaction patterns for Mometasone Furoate (Furo), primarily related to its metabolism and the potential for additive systemic effects.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substances/Categories Interaction Outcome Statement
Pharmacokinetic (Metabolism) Strong Cytochrome P450 3A4 (CYP3A4) Inhibitors (e.g., Ketoconazole) Co-administration is documented to increase the systemic exposure (plasma concentration) of Mometasone Furoate.
Pharmacodynamic (Additive Effect) Other Corticosteroid Products (Inhaled, Oral, Injectable, or Topical) Combined use carries an increased additive risk of systemic corticosteroid effects, including Hypercorticism and Adrenal Suppression.

The official interaction profile is structured around the role of the CYP3A4 enzyme in the medicine's clearance. The documentation notes that this metabolic pathway is sensitive to inhibition, which alters the concentration of the nasal spray's active component in the body. Furthermore, the regulatory guidance highlights that combining Furo with any other form of steroid treatment poses a collective risk of increasing systemic effects due to their shared pharmacological class.

Restrictions and Specific Considerations

There are no specific medicinal products formally listed as contraindicated solely based on a drug-drug interaction mechanism in the official labeling. No mandatory timing separation rules (e.g., "administer X hours apart") are documented for this nasal spray formulation. However, regulatory sources advise caution in patients with hepatic impairment (liver disease), as reduced metabolic clearance could potentially lead to increased systemic exposure and effects. Interactions with food, alcohol, or specific herbal products are not explicitly documented in the official prescribing information for the nasal spray.

Mechanism of Action

Inhibition of Kidney Salt Transport

This drug acts as a direct inhibitor of the Na^+- K^+- 2 Cl^- cotransporter (NKCC2) protein. This transporter is located on the cells lining the thick ascending limb of the Loop of Henle in the kidney. The molecular blockade prevents the reabsorption of sodium and chloride ions from the tubular fluid back into the bloodstream. This leads to an increase in the excretion of water and salt, resulting in the alteration of the body's fluid volume.


Modulation of Systemic Circulatory Dynamics

The drug also engages mechanisms that influence the peripheral vasculature, promoting the production of certain prostaglandins. This molecular influence leads to the subsequent vessel dilation, which reduces resistance in the circulatory system. These two mechanisms result in additive physiological effects by simultaneously affecting both fluid volume and the force required to circulate blood.

Dosage and Administration Information

Official Administration Guidelines

Furosemide is available for Oral (tablet, solution), Intravenous (IV), and Intramuscular (IM) administration, with a specialized Subcutaneous (SC) delivery system available for specific indications. Dosage is always individualized based on the patient's response, necessitating close monitoring, and the lowest effective dose should be used.


Dosing and Timing

Administration Method Adult Dosing (Typical Range) Frequency/Timing Constraint
Oral (Tablet/Solution) Initial: 20 mg to 80 mg Take on an empty stomach. Often given once or twice daily, or on alternate days.
Intravenous (IV) Initial: 20 mg to 40 mg Administer slowly over 1 to 2 minutes. Infusion rate must not exceed 4 mg/minute.
Pediatric (Oral/IV/IM) Initial: 1 mg/kg to 2 mg/kg IV/IM dose increases by 1 mg/kg not sooner than 2 hours after previous dose (max 6 mg/kg).

Procedural and Missed-Dose Instructions

Route Transition: Parenteral (IV/IM) use should transition to oral administration as soon as clinically practical. The parenteral route is reserved for when a rapid effect is required or when gastrointestinal absorption is impaired.

Preparation: Visually inspect the Furosemide injection solution for particulate matter and discoloration before use; any unused portion should be discarded.

Missed Dose: For oral administration, if a dose is missed, take it as soon as possible. However, if it is almost time for the next scheduled dose, skip the missed dose and continue the regular schedule. Do not double the dose to compensate for the missed one.

Drug-Food Interaction: Oral Furosemide and sucralfate must be separated by at least two hours due to sucralfate potentially reducing Furosemide absorption.

Recent Clinical Evidence

Research evidence / Overview of studies for Furo


Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

The clinical evaluation for Furo's use in managing symptoms of allergic rhinitis—which covers both seasonal allergies (e.g., hay fever) and perennial, year-round allergies—was studied in multiple trials, including Randomized Controlled Trials (RCTs) and meta-analyses. Researchers monitored changes in Total Nasal Symptom Scores (TNSS), a key outcome related to physical discomfort that combines individual symptoms like congestion, sneezing, and itching. The research provides context regarding patterns observed in the measurements over short periods, typically two to four weeks.

While the core research contributes to the broader evidence landscape, evidence quality varies across studies when comparing Furo directly against some other types of nasal steroids. The research included a broad spectrum of individuals, from adults to adolescents and children (down to age two or six, depending on the regulatory region).


Evidence for Use in Nasal Polyposis

For the treatment of nasal polyps in adults, Furo was evaluated in dedicated Randomized Controlled Trials (RCTs) over several months. The main outcomes researchers monitored included the Polyp Grade Score, an objective measure of polyp size and extent, and patient-reported nasal congestion and obstruction scores. Research highlights changes measured during the study period for both the objective polyp size and the patient-reported symptoms over an intermediate follow-up duration of three to four months.


Areas of Research Uncertainty and Study Gaps

One key area of research uncertainty is the variability in findings when Furo was compared head-to-head with some other intranasal corticosteroids in clinical trials. Additionally, while research has been conducted for the two approved indications, research is limited regarding non-polyp Chronic Rhinosinusitis (CRS) without surgical intervention. Follow-up durations were limited in some of the initial trials, suggesting that long-term effects are not fully established for all subgroups.

Frequently Asked Questions (FAQ)

Common questions about Furo (FAQ)


Q: How long does it typically take for Furo to start working?

According to official product information, when Furo is taken by mouth, the diuretic effect (increased urination) typically begins within 1 hour. The peak effect usually occurs within the first one to two hours after administration.


Q: Is it normal to feel more tired than usual when first starting Furo?

Regulatory documents indicate that side effects related to fluid or electrolyte loss, such as weakness or lethargy (extreme tiredness), are known potential effects of this medication. These feelings are associated with the drug's documented effects, particularly related to fluid changes.


Q: What is the typical duration of Furo's effect after one dose?

Official labeling states that the diuretic effect of Furo, when taken orally, generally lasts for 6 to 8 hours per dose. The duration of effect is a factor that may influence the timing of the dose.


Q: What kind of monitoring (blood tests, etc.) is usually required when taking Furo?

Official information emphasizes that frequent monitoring of certain factors is recommended, especially when starting the drug. Monitoring typically involves blood tests to check serum electrolytes (like potassium, calcium, and magnesium), as well as kidney function indicators like BUN and creatinine. Blood glucose levels may also be monitored.


Q: Why is Furo sometimes given in combination with other drugs?

Regulatory information indicates that Furo may be used alongside other antihypertensive agents (medications for high blood pressure). This combination approach may sometimes require a reduction in the dosage of the other blood pressure medicines to maintain safe and effective treatment.


Q: Is Furo considered a high-risk medication for most people?

Furosemide carries a Boxed Warning in its official label. This warning highlights the risk of causing profound diuresis (excessive fluid loss), which can lead to severe water and electrolyte depletion. For this reason, the drug is used under close medical supervision.


Q: Is there a preferred time of day to take Furo for best results?

While specific dosing times are determined by a physician, regulatory information advises avoiding administration at bedtime. This timing is suggested to minimize the drug's potential to interrupt sleep due to increased urination.


Q: Can Furo cause changes in appetite or weight?

Official documentation lists anorexia (loss of appetite) as a possible adverse reaction. Any notable change in weight, especially early in treatment, is generally considered to be related to the medication's intended effect of causing the body to lose excess fluid.


Q: How quickly does Furo leave your system after you stop taking it?

Regulatory sources state that the elimination half-life of Furosemide in people with normal kidney function is approximately 2 hours. This is the time it takes for half of the drug to be eliminated from the system.


Q: Does taking Furo affect the results of any routine lab tests?

Yes, official labeling notes that Furosemide can affect various lab results. Specifically, it may cause changes in serum electrolytes and may lead to an increase in blood glucose levels, which may affect urine glucose tests.


Q: Can taking Furo affect my sleep schedule?

The medication causes patients to urinate more frequently. Because of this effect, general advice in official information recommends avoiding administration close to bedtime, as increased nighttime urination can potentially disrupt sleep.


Q: Can Furo affect blood sugar levels in non-diabetic people?

Yes, official documents indicate that Furosemide may cause an increase in blood glucose levels. Changes in glucose tolerance tests have been observed, and, rarely, the onset of diabetes mellitus has been reported.


Q: Does Furo interact with common pain relievers like ibuprofen?

Official sources indicate that Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which include ibuprofen, may interact with this medication. Concomitant use of NSAIDs may reduce the effectiveness of Furosemide and may increase the risk of developing certain kidney problems.


Q: Does Furo interact with cold and flu medications?

For patients being treated for high blood pressure, official information advises caution with some over-the-counter cold symptom products. It is noted that these products may contain ingredients that could potentially increase blood pressure.


Q: Can Furo be split or crushed if someone has trouble swallowing pills?

According to regulatory summaries, Furosemide tablets can often be cut or crushed. However, as this depends on the specific formulation, it is important to consult with a healthcare provider or pharmacist regarding a specific tablet formulation.


Q: Do people need to limit salt intake while on Furo?

Official information mentions that fluid and electrolyte depletion may occur, especially with high doses and a restricted salt intake. It is necessary to follow the specific instructions from a healthcare provider regarding the appropriate amount of salt and potassium in the diet while taking this medication.


Q: Why does my doctor want me to take Furo in the morning?

Furo is a strong diuretic that causes increased urination. Taking the drug in the morning or early afternoon is a common practice to help minimize the chance of the drug's diuretic effect disrupting sleep.


Q: Is there a link between Furo and any skin reactions or rashes?

Yes, the official labeling for Furo includes a list of dermatologic (skin) and hypersensitivity reactions. These can include photosensitivity (increased sun sensitivity), rash, itching, and in rare cases, more severe skin reactions.


Q: Is Furo known to cause any issues with memory or concentration?

Central Nervous System effects are documented for Furo. Symptoms such as drowsiness, dizziness, and vertigo are possible signs of fluid or electrolyte imbalance that may affect concentration.


Q: Is Furo the same type of medicine as diuretics like Lasix?

Yes, Lasix is the long-established brand name for the generic medication Furosemide. Therefore, Furosemide is the active ingredient found in the product known as Lasix.


Q: Is it true that Furo can lower potassium levels?

Yes, regulatory information explicitly states that hypokalemia (low potassium) may develop while taking Furosemide, especially if high fluid output occurs. Due to this risk, the monitoring of potassium levels is a recommended component of therapy.


Q: Does Furo interact with other corticosteroid products?

Official labeling advises that concurrent use with corticosteroids (like prednisone) may increase the risk of developing hypokalemia (low potassium). A healthcare provider may monitor the patient closely if both types of medications are prescribed.


Q: Do older adults react differently to Furo compared to younger people?

While clinical studies have not identified major differences in response, official documents advise caution in dose selection for older adults, often suggesting starting at the low end of the dosing range. This approach is due to the potential for excessive diuresis (fluid loss) to cause complications in this population.


Q: Are there any known side effects of Furo on heart rhythm?

Serious electrolyte loss is a known risk with this medication. Symptoms of such an imbalance can include experiencing rapid or pounding heartbeats (a fast or atypical heart rhythm). This potential effect underscores why monitoring of electrolyte levels is an important part of treatment.

How should Furo be stored and disposed of?

How to Store and Dispose of Furosemide

Storage Requirements

Furosemide must be stored in a closed container at room temperature and protected from excessive heat and moisture. The product must be kept from freezing. Specific temperature ranges, such as 20 C to 25 C (68 F to 77 F), are often specified for certain formulations. Liquid forms (Injections) require protection from light and must be discarded if the solution becomes discolored. All forms of Furosemide must be kept out of the reach of children.

Disposal Instructions

Any unused or expired Furosemide should be disposed of in accordance with local requirements. The preferred method is typically a drug take-back program. If a take-back program is not available, the FDA advises mixing the medicine with an undesirable substance (such as dirt or coffee grounds) and placing the mixture in a sealed container before disposal in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Furo found in:

A-Z Index: